2020
Primary Treatment Selection for Clinically Node-Negative Merkel Cell Carcinoma of the Head and Neck
Jacobs D, Olino K, Park HS, Clune J, Cheraghlou S, Girardi M, Burtness B, Kluger H, Judson BL. Primary Treatment Selection for Clinically Node-Negative Merkel Cell Carcinoma of the Head and Neck. Otolaryngology 2020, 164: 1214-1221. PMID: 33079010, DOI: 10.1177/0194599820967001.Peer-Reviewed Original ResearchConceptsNode-negative Merkel cell carcinomaLymph node evaluationImproved overall survivalPrimary tumor excisionMerkel cell carcinomaCase volumeOverall survivalSurgical managementCell carcinomaTumor excisionTreatment selectionNode evaluationCox proportional hazards regressionGuideline-recommended carePrimary treatment selectionNational Cancer DatabaseNode-negative diseasePercentage of patientsRetrospective cohort analysisInitial surgical managementKaplan-Meier analysisWide local excisionProportional hazards regressionRates of receiptInitial management
2019
Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling
Khan SA, Ci B, Xie Y, Gerber DE, Beg MS, Sherman SI, Cabanillas ME, Busaidy NL, Burtness BA, Heilmann AM, Bailey M, Ross JS, Sher DJ, Ali SM. Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling. Head & Neck 2019, 41: 1928-1934. PMID: 30758123, PMCID: PMC6542589, DOI: 10.1002/hed.25634.Peer-Reviewed Original ResearchConceptsAnaplastic thyroid cancerComprehensive genomic profilingThyroid cancerGenomic alterationsGenomic profilingMedian patient ageAggressive thyroid cancerYears of agePotential therapeutic significanceUnique mutation patternsDifferent molecular pathwaysATC specimensPatient ageCommon genomic alterationsKRAS alterationsCancer-related genesBRAF V600ETherapeutic significanceCancerBRAFMolecular pathwaysPatientsMutation patternsNumber alterationsNRAS
2017
NSD1- and NSD2-damaging mutations define a subset of laryngeal tumors with favorable prognosis
Peri S, Izumchenko E, Schubert AD, Slifker MJ, Ruth K, Serebriiskii IG, Guo T, Burtness BA, Mehra R, Ross EA, Sidransky D, Golemis EA. NSD1- and NSD2-damaging mutations define a subset of laryngeal tumors with favorable prognosis. Nature Communications 2017, 8: 1772. PMID: 29176703, PMCID: PMC5701248, DOI: 10.1038/s41467-017-01877-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCohort StudiesFemaleGene Expression Regulation, NeoplasticHistone MethyltransferasesHistone-Lysine N-MethyltransferaseHumansIntracellular Signaling Peptides and ProteinsLaryngeal NeoplasmsMaleMiddle AgedMutationNuclear ProteinsPrognosisRepressor ProteinsSquamous Cell Carcinoma of Head and NeckConceptsUseful clinical metricSquamous cell carcinomaLaryngeal cancer patientsPoor overall survivalIndependent validation cohortDistinct prognostic outcomesMolecular prognostic biomarkersOverall survivalCancer Genome AtlasFavorable prognosisBetter prognosisValidation cohortCell carcinomaCancer patientsLaryngeal tumorsLaryngeal cancerPrognostic outcomesTreatment stratificationPrognostic biomarkerNasal cavityOral cavityHigh recurrenceAnatomical sitesPatient stratificationCancer subtypes
2016
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
Chow LQM, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M, Berger R, Eder JP, Burtness B, Lee SH, Keam B, Kang H, Muro K, Weiss J, Geva R, Lin CC, Chung HC, Meister A, Dolled-Filhart M, Pathiraja K, Cheng JD, Seiwert TY. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. Journal Of Clinical Oncology 2016, 34: 3838-3845. PMID: 27646946, PMCID: PMC6804896, DOI: 10.1200/jco.2016.68.1478.Peer-Reviewed Original ResearchConceptsOverall response rateNeck squamous cell carcinomaProgression-free survivalSquamous cell carcinomaMetastatic headExpansion cohortPD-L1Cell carcinomaAnti-programmed death-1 antibodySix-month progression-free survivalTreatment-related adverse eventsEnd pointDeath-1 antibodyDose of pembrolizumabAntitumor activityPrimary end pointSecondary end pointsHuman papillomavirus (HPV) statusPD-L1 expressionOverall survival rateDurable antitumor activityFrequent dosing scheduleAssociation of responseAdvanced HNSCCM HNSCC
2014
Markers of Epithelial to Mesenchymal Transition in Association with Survival in Head and Neck Squamous Cell Carcinoma (HNSCC)
Pectasides E, Rampias T, Sasaki C, Perisanidis C, Kouloulias V, Burtness B, Zaramboukas T, Rimm D, Fountzilas G, Psyrri A. Markers of Epithelial to Mesenchymal Transition in Association with Survival in Head and Neck Squamous Cell Carcinoma (HNSCC). PLOS ONE 2014, 9: e94273. PMID: 24722213, PMCID: PMC3983114, DOI: 10.1371/journal.pone.0094273.Peer-Reviewed Original ResearchMeSH KeywordsAutomationBiomarkers, TumorCarcinoma, Squamous CellCohort StudiesEpithelial-Mesenchymal TransitionFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHead and Neck NeoplasmsHumansImage Processing, Computer-AssistedImmunohistochemistryKaplan-Meier EstimateMaleMultivariate AnalysisNeoplasm MetastasisPhenotypePrognosisProportional Hazards ModelsSquamous Cell Carcinoma of Head and NeckTreatment OutcomeConceptsProgression-free survivalSquamous cell carcinomaOverall survivalCell carcinomaE-cadherinPrimary squamous cell carcinomaNeck squamous cell carcinomaHigh-risk HNSCCKaplan-Meier analysisNovel therapeutic approachesMesenchymal transition phenotypeHigh metastatic potentialLow E-cadherinImproved OSInferior OSIndependent predictorsPoor prognosisCarcinoma prognosisClinicopathological parametersInclusion criteriaTherapeutic approachesTransition phenotypeMetastatic potentialMesenchymal transitionProtein expression analysis
2013
Baseline health perceptions, dysphagia, and survival in patients with head and neck cancer
Lango MN, Egleston B, Fang C, Burtness B, Galloway T, Liu J, Mehra R, Ebersole B, Moran K, Ridge JA. Baseline health perceptions, dysphagia, and survival in patients with head and neck cancer. Cancer 2013, 120: 840-847. PMID: 24352973, PMCID: PMC3951722, DOI: 10.1002/cncr.28482.Peer-Reviewed Original ResearchConceptsDisease-related deathPatient-reported health stateDisease recurrenceBaseline dysphagiaWeight lossNeck cancerHealth perceptionPatient-reported dysphagiaECOG performance statusAdvanced T classificationProspective cohort studyGeneral health perceptionRisk of deathNeck cancer patientsPatient-reported measuresLogistic regression analysisHealth statesCurative intentDysphagia measuresCohort studyIdentifies patientsPerformance statusEuroQol-5DMale patientsSWAL-QOL
2010
Increased Recurrences Using Intensity-Modulated Radiation Therapy in the Postoperative Setting
Turaka A, Li T, Sharma NK, Li L, Nicolaou N, Mehra R, Burtness B, Cohen RB, Lango MN, Horwitz EM, Ridge JA, Feigenberg SJ. Increased Recurrences Using Intensity-Modulated Radiation Therapy in the Postoperative Setting. American Journal Of Clinical Oncology 2010, 33: 599-603. PMID: 21063195, DOI: 10.1097/coc.0b013e3181c4c3cc.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge DistributionAgedAged, 80 and overCarcinoma, Squamous CellCohort StudiesFemaleHead and Neck NeoplasmsHumansIncidenceMaleMiddle AgedNeck DissectionNeoplasm Recurrence, LocalNeoplasm StagingPostoperative CarePostoperative PeriodPrognosisRadiotherapy DosageRadiotherapy, Intensity-ModulatedRetrospective StudiesRisk AssessmentSex DistributionSurvival AnalysisTreatment FailureConceptsPatterns of failurePostoperative therapyRadiation therapyLocal failureMarginal failureNeck cancerRegional failureRetrospective single-institution studyFox Chase Cancer CenterHigh-risk PTVLocoregional failure rateAddition of chemotherapySingle-institution studySquamous cell carcinomaIntensity-modulated radiation therapyPersistence of diseaseLow-risk PTVConcurrent cisplatinCurative intentDefinitive radiationDefinitive RTNodal recurrencePostoperative settingMedian ageNodal stageNonsurgical management of oropharyngeal, laryngeal, and hypopharyngeal cancer: The Fox Chase Cancer Center experience
Andrews G, Lango M, Cohen R, Feigenberg S, Burtness B, Mehra R, Ahmed S, Nicolaou N, Gaughan J, Ridge JA. Nonsurgical management of oropharyngeal, laryngeal, and hypopharyngeal cancer: The Fox Chase Cancer Center experience. Head & Neck 2010, 33: 1433-1440. PMID: 21928415, DOI: 10.1002/hed.21615.Peer-Reviewed Original ResearchMeSH KeywordsCancer Care FacilitiesCarcinoma, Squamous CellChemoradiotherapy, AdjuvantCohort StudiesDisease-Free SurvivalFemaleHumansHypopharyngeal NeoplasmsLaryngeal NeoplasmsMaleMiddle AgedNeoplasm Recurrence, LocalOropharyngeal NeoplasmsProportional Hazards ModelsRadiotherapy, ConformalRadiotherapy, Intensity-ModulatedRetrospective StudiesSalvage TherapySmokingConceptsSurvival of patientsNumber of patientsOropharyngeal cancerHypopharyngeal cancerT classificationLaryngeal cancerFox Chase Cancer Center experienceRetrospective single-institution cohort studyMultivariate analysisSingle-institution cohort studyRecurrent oropharyngeal cancerCancer Center experienceRecurrence-free survivalSubset of patientsLaryngeal cancer patientsDisease-related deathEarly T classificationHypopharyngeal cancer treatmentChemotherapy useCurative intentLocoregional controlCohort studyCurrent smokersOverall survivalSalvage surgeryNuclear Localization of Signal Transducer and Activator of Transcription 3 in Head and Neck Squamous Cell Carcinoma Is Associated with a Better Prognosis
Pectasides E, Egloff AM, Sasaki C, Kountourakis P, Burtness B, Fountzilas G, Dafni U, Zaramboukas T, Rampias T, Rimm D, Grandis J, Psyrri A. Nuclear Localization of Signal Transducer and Activator of Transcription 3 in Head and Neck Squamous Cell Carcinoma Is Associated with a Better Prognosis. Clinical Cancer Research 2010, 16: 2427-2434. PMID: 20371693, PMCID: PMC3030188, DOI: 10.1158/1078-0432.ccr-09-2658.Peer-Reviewed Original ResearchConceptsLonger progression-free survivalNeck squamous cell cancerNeck squamous cell carcinomaProgression-free survivalSquamous cell cancerSquamous cell carcinomaPittsburgh Medical CenterTranscription 3Early Detection Research NetworkCurative intentPrognostic roleSurgical resectionBetter prognosisSignal transducerCell cancerCell carcinomaFavorable outcomeSurvival prognosisClinicopathologic parametersMedical CenterIndependent cohortLower riskTest cohortHNSCCSurvival analysis
2005
Quantitative Determination of Nuclear and Cytoplasmic Epidermal Growth Factor Receptor Expression in Oropharyngeal Squamous Cell Cancer by Using Automated Quantitative Analysis
Psyrri A, Yu Z, Weinberger PM, Sasaki C, Haffty B, Camp R, Rimm D, Burtness BA. Quantitative Determination of Nuclear and Cytoplasmic Epidermal Growth Factor Receptor Expression in Oropharyngeal Squamous Cell Cancer by Using Automated Quantitative Analysis. Clinical Cancer Research 2005, 11: 5856-5862. PMID: 16115926, DOI: 10.1158/1078-0432.ccr-05-0420.Peer-Reviewed Original ResearchConceptsEpidermal growth factor receptorOropharyngeal squamous cell cancerLocal recurrence rateSquamous cell cancerEGFR expression levelsEGFR expressionCell cancerRecurrence rateEGFR levelsHigh tumorInferior disease-free survivalExpression levelsNeck squamous cell carcinomaEpidermal growth factor receptor expressionTumor EGFR levelsGrowth factor receptor expressionProtein expressionDisease-free survivalOropharyngeal cancer casesSquamous cell carcinomaFactor receptor expressionMedian expression levelCy5-conjugated antibodiesEGFR protein expressionNuclear EGFR levels